Table 1.

Details of the studies included in the analysis.

Legend:

*PT =* patients; *SG =* skin grafts; *N* = number; *R =* range; *NM* = not mentioned; *loc =* local/topical antibiotics; *NS =* not specified; *ir* = not consecutive for all patients; *sys* = systemic antibiotics; SP = split skin graft; *SkinM* = skin malignancy; *FT* = full thickness skin graft; *NOT =* no tie-over group; *TO* = tie-over group; *BCC =* basal cell carcinoma; *SO =* sofratulle; *FM =* polyurethane foam; *HN* = head and neck; *Ex* = extremity; \* graft assessment per 10%; \*\* 9 patients with non-adherent gauze and 1 patient with proflavin wool; \*\*\* cartella shields and eye pads; \*\*\* 75-100% graft take

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, year, country | Study period | PT or SG | Median age (R) | use of ab | Indication for surgery (N) | Type of graft (N) | Dressing (N) | Graft/defect size (R) | Graft take in percentage | Incomplete (I) graft take or failure (F) | Complications (N) | Location  |
| Atherton 2007, UK | 2004 - 2005 | 59 | 76 (40-95) | NM | Lesions | SP (8) FT (51) | Jellonet/profalvin (30) vs Allevyn (29) | NM | 92.3 % vs 90.3%\* | 2 out of 51 (Allevyn group) | Poor graft (2)Infection (1 vs 1) | HN (50) Ex (9) |
| Audain2015, UK | 2009-2014 | 50 | 75 (49-96) | NM | SkinM | FT | Mepitel bolster | 52.4cm2 | 96% | 4% | Infection (1)Bleeding (1) | Leg |
| Chasapi2016, UK | NM | 27 | NM | Yes (loc) | SkinM | FT | NOT | NM | 100% | NM | NM | HN |
| Davenport1988,UK | NM | 38 (40SG) | NM | Yes (loc only NOT) | SkinM (37), other (3) | FT | NOT (20) vs TO (materials NS; 20) | NM | 95% vs 95% | 5% (I) vs 5% (F) | None | HN |
| Dhillon 2014, UK | 2006 - 2008 | 70 | 62 | Yes (loc) | SkinM | FT | NOT (35) vs proflavin wool (35) | 225-3600 mm2 | 89% vs 80% | 11% (I) vs 6% (F) and 20% (I)  | Infection (9% vs 26%) | HN |
| de Gado 2008, IT | 2004 - 2006 | 212 | 58.1 (18-80) | Yes (NS) | SkinM |  FT | dried gauzes (106) vs polyurethane sponge (106) | NM | 89.6% vs 97.1% | NM | NS 10.4% vs 2.9%  | HN (99) Ex (113) |
| Harb 2010, UK | 2001 - 2008 | 79 | NM | NM | SkinM | FT | NOT | 31 mm (20-53mm) | 100% | None | Redness (3)Suture reaction (1) | Nose |
| Keh 2017, UK | NM | 128 | 71 | Yes (loc) | SkinM 57.6%, other 42.4% | FT | NOT (100) vs TO (materials NS; 25) | 187 mm2 (SD 414.7) | 82% (NOT vs 76% TO) | 13.6% (<60% take) | 12% incomplete excision | HN |
| Langtry 1998, UK | NM | 30 | 69 (39-95) | Yes (loc ir) | Skin tumors | FT | NOT\*\* | 20mm (8-45) | 93% | 2 out of 30 | None | HN (27) Ex (3) |
| Mehta 1979, UK | 1973 - 1977 | 109 | NM | Yes (sys) | SkinM (87, other (22) | FT | NOT\*\*\*  | 1.2 - 3.5 cm | 100% | NM | Poor color match (1) | Orbita |
| Nakamura 2011, JP | 2007 - 2008 | 26 | 73.5 (38-97) | Yes (NS) | Skin tumors | FT | multilayered polyurethane foam | 17.4 cm2 (3-80) | 88.9% (23.1-100) | 1 out of 26 (4%) | NM | HN (19) other (7) |
| Sapountzis2011, KOR | NM | 23 | 73 | NM | SkinM | FT | Surgical scrub sponge | 3.8 cm (2.4-6.1) | 90% | NM | NM | HN |
| Shimizu2013, USA | 2010-2011 | 96 | 71 | Yes (loc only NOT) | SkinM | FT | NOT 49 vs TO (petrolatum gauze) 47  | 1.9 vs 2.0 cm | 84% vs 85% | 8 vs 7 | Generalized crusting or sloughing | HN (74)Other (22) |
| Struk2017, FR | 2011-2016 | 70 | 70 (17) | NM | SkinM | FT | TO (NS) | 12 cm 2 (18) | 91.4% | 8.6% | Hematoma (8)Infection (1)Venous thrombosis (2) | Leg |
| Yuki 2017,JAP | 2009 - 2014 | 266 | 76 (26-99) | NM | SkinM (188) other (78) | SP (46) FT (220) | Sofratulle (148) vs polyurethane foam (118) | 4 cm (1.4 - 29) | 90 % vs 88 % \*\*\* | 10% vs 11% \*\*\*\* | Infection (SO=7 FM=10) Hematoma (SO=6 FM=3) | HN (120) Ex (146) |